Q1 Earnings Forecast for Immunocore Issued By HC Wainwright

Key Points

• HC Wainwright cut its Q1 2027 EPS estimate for Immunocore to $0.17 from $0.18, while maintaining a Buy rating and an $80 price target.
• Immunocore’s latest quarter missed expectations: EPS was -$0.28 versus a -$0.17 consensus, and revenue was $102.22 million compared with estimates of $152.09 million.
• Analyst sentiment is mixed but leans positive: MarketBeat reports a Moderate Buy consensus and an average price target of $53, while HC Wainwright’s target was reduced from $100 to $80.

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR - Free Report) - Analysts at HC Wainwright decreased their Q1 2027 earnings per share estimates for shares of Immunocore in a research report issued on Tuesday, November 10th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings per share of $0.17 for the quarter, down from their previous forecast of $0.18. HC Wainwright has a "Buy" rating and a $80.00 price target on the stock. The consensus estimate for Immunocore's current full-year earnings is ($0.04) per share. HC Wainwright also issued estimates for Immunocore's Q2 2027 earnings at $0.26 EPS, Q4 2027 earnings at $0.52 EPS and FY2027 earnings at $1.34 EPS.

Immunocore (NASDAQ:IMCR - Get Free Report) last announced its earnings results on Friday, November 6th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.11). Immunocore had a negative net margin of 7.48% and a negative return on equity of 7.96%. The business had revenue of $102.22 million for the quarter, compared to the consensus estimate of $152.09 million.

Other equities research analysts have also recently issued reports about the stock. TD Cowen upgraded shares of Immunocore to a "strong-buy" rating in a research note on Monday, August 24th. Wall Street Zen lowered shares of Immunocore from a "buy" rating to a "hold" rating in a research report on Tuesday, July 28th. JPMorgan Chase & Co. initiated coverage on shares of Immunocore in a research note on Friday, August 21st. They set an "overweight" rating and a $50.00 target price on the stock. Morgan Stanley set a $43.00 price target on shares of Immunocore in a research report on Friday, August 7th. Finally, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Immunocore in a research note on Thursday, October 15th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $53.00.

Immunocore Trading Up 2.0%

NASDAQ:IMCR opened at $32.38 on Wednesday. Immunocore has a 1 year low of $27.50 and a 1 year high of $40.71. The stock has a market cap of $1.67 billion, a price-to-earnings ratio of -49.81 and a beta of 0.82. The business has a fifty day moving average of $31.46 and a 200-day moving average of $31.70. The company has a debt-to-equity ratio of 0.94, a quick ratio of 4.44 and a current ratio of 4.62.

Institutional Trading of Immunocore

Several institutional investors have recently modified their holdings of IMCR. Engineers Gate Manager LP boosted its stake in Immunocore by 334.3% during the second quarter. Engineers Gate Manager LP now owns 60,327 shares of the company's stock valued at $1,915,000 after buying an additional 46,435 shares in the last quarter. Braidwell LP bought a new stake in Immunocore in the second quarter worth about $16,552,000. Eversept Partners LP bought a new stake in Immunocore in the first quarter worth about $1,183,000. Public Employees Retirement System of Ohio acquired a new stake in Immunocore in the 2nd quarter valued at about $2,145,000. Finally, Stempoint Capital LP acquired a new stake in Immunocore in the 1st quarter valued at about $1,916,000. Institutional investors and hedge funds own 84.50% of the company's stock.

Trending Headlines about Immunocore

Here are the key news stories impacting Immunocore this week:

• Positive Sentiment: Shares crossed above their 200-day moving average, a potentially supportive technical signal, despite the earnings miss referenced in the report. Immunocore shares cross above 200-day moving average
• Positive Sentiment: HC Wainwright maintained its Buy rating and an $80 price target—about 147% above the cited $32.38 share price—though the target was reduced from $100. HC Wainwright rating and price target
• Neutral Sentiment: Immunocore presented at the Society for Immunotherapy of Cancer’s 2026 annual meeting; the available article is a slideshow and does not detail specific new clinical findings. SITC 2026 presentation slideshow
• Negative Sentiment: HC Wainwright trimmed its 2027 EPS forecasts for Q1 ($0.17 from $0.18), Q2 ($0.26 from $0.29) and full-year 2027 ($1.34 from $1.36). It raised its Q4 estimate to $0.52 from $0.49, but the overall revisions were lower.
• Negative Sentiment: The cut in HC Wainwright’s price target from $100 to $80 may weigh on sentiment, even with its Buy rating retained.

Immunocore Company Profile

Immunocore is a biotechnology company that develops T cell receptor (TCR)-based medicines for cancer and other diseases. Its ImmTAX platform is designed to create therapies that direct the body's T cells toward targets inside cells, including targets that may be difficult for conventional antibody treatments to reach. The company's marketed medicine, KIMMTRAK (tebentafusp-tebn), is a TCR-based therapy approved in the United States and other markets for certain patients with unresectable or metastatic uveal melanoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.